RMP exposure is lower in HIV-infected TB patients receiving intermittent than daily anti-tuberculosis treatment.

We compared the pharmacokinetics of rifampicin (RMP) during daily and intermittent (thrice weekly) anti-tuberculosis treatment in human immunodeficiency virus infected tuberculosis patients. Patients treated with a thrice-weekly regimen had significantly lower plasma peak concentration, area under the time concentration curve from 0 to 24 h and higher oral clearance of RMP than those treated with the daily regimen. The median values were respectively 3.7 and 6.4 μg/ml (P < 0.001), 20.7 and 29.4 μg/ml.h (P = 0.03) and 21.7 and 15.3 ml/min (P = 0.03).

[1]  H. McIlleron,et al.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes. , 2013, The Journal of infectious diseases.

[2]  S. Swaminathan,et al.  Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. , 2010, American journal of respiratory and critical care medicine.

[3]  H. McIlleron,et al.  Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients , 2006, Antimicrobial Agents and Chemotherapy.

[4]  J. Sackoff,et al.  Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  S. Swaminathan,et al.  Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease , 2004, Antimicrobial Agents and Chemotherapy.

[6]  A. K. Kumar,et al.  A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine , 2004 .

[7]  F. Fountain,et al.  Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. , 2001, Chest.

[8]  M. Narita,et al.  Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  A. Vernon,et al.  Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid , 1999, The Lancet.